Company Overview and News

24
Permian Boom Jeopardized By Pipeline Troubles

2018-06-10 oilprice
Irina is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing on the oil and gas industry.
PIO APA NBL CXO EPD PIONF

48
Trading Oil And Oil Stocks The Next 2 Years

2018-05-14 seekingalpha
Oil stocks have a lot longer runway than actual oil, be ready to hold on for a while.
PIO USO RDS.B RDS.A RDSB ECA RDSA PIONF USOU ECA HP XES CVX RYDBF RYDAF OXY

0
Korean Refining, Chemical, And Utility Outlook: Oil Price To Face Inflection Point In May

2018-04-30 seekingalpha
We raise our oil price forecast in light of tight crude oil supply and geopolitical risks; we see negotiations on Iran’s nuclear program, scheduled for May, as an important event.
PIO PIONF

1
Pioneer Resources' caesium deposit continues to deliver ahead of mineral resource upgrade

2018-04-19 proactiveinvestors.com.au
Pioneer Resources Ltd (ASX:PIO) has provided a drilling update for its Pioneer Dome Project in the Eastern Goldfields of Western Australia, including the Sinclair Zone caesium deposit.
PIO EGS PIONF EGDD ESGFF

1
Long Ball Play, Torchlight Energy And Its Bet On The Orogrande

2018-04-16 seekingalpha
The Orogrande is a largely ignored sub-basin in the Permian with similar characteristics to the better known Delaware, and Midland basins.
PIO PIEX CXO PIONF FANG

208
Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.
SIE PIO PANRF HAV PAN KBGCF MCR FCX ECSIF IGO VIC BAR AOU HIG PLM.RT TAKRF UMICF SNNAF FQM LGI MCRZF BXTMF MLX PSDNF POM CDU RGARF CHK VLKAF MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF HMI POS AUZ RNX GME AAPL FQVLF AQR MBL PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF KATFF MLXEF OZMLF PLM S CNJ AZRMF HLPCF BHP OZL ARV

3
Pioneer Resources: Still Priced For Perfection?

2018-03-12 seekingalpha
As I suggested last year at this time, PXD was priced to perfection and under-performed its peer Conoco Phillips over the past year.
COP PIO PXD PIONF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...